Drawing on our executive search practice, we put this together to give employers a grounded, practical view they can act on. A board launching a MedTech CEO search should understand several things before it starts, because the decisions made in the first few weeks, about the mandate, the profile, and the process, largely determine the outcome. Most disappointing MedTech CEO searches were compromised at the definition stage, not the candidate stage, and boards that get the setup right have far better outcomes.
Key Takeaways
- Most search failures trace back to how the search was defined, not the candidates.
- The board must align on the mandate before defining the profile.
- Regulatory and clinical fluency requirements should be explicit, not assumed.
- The realistic candidate pool is smaller than boards typically expect.
- Process speed and candidate experience materially affect the outcome.
Align on the Mandate First
Before defining a profile, the board needs to agree on what the next CEO is actually being asked to do: drive commercial scale on an approved portfolio, navigate a critical regulatory pathway, prepare the company for a sale or IPO, turn around a troubled situation, or something else. These mandates call for materially different leaders, and boards that skip this alignment end up debating candidates as proxies for a strategic disagreement they never resolved. Getting explicit agreement on the mandate, and on what success looks like in two to three years, is the single highest-return step in the process.
Be Explicit About Regulatory and Clinical Requirements
Boards often assume a strong CEO will handle the regulatory dimension, or they treat it as delegable to the regulatory function. In device companies, where the pathway shapes strategy, timelines, and capital, this assumption is risky. The board should decide explicitly how much direct regulatory and clinical fluency the CEO needs given the company’s stage and portfolio, a pre-approval company with a demanding pathway needs far more than a commercial-stage company with a mature portfolio, and build that into the specification rather than leaving it to be discovered in interviews.
Calibrate Expectations About the Pool
MedTech CEO candidates who combine regulatory judgment, clinical understanding, commercial capability, and CEO-level leadership are genuinely scarce, and boards frequently begin with a profile that describes a person who barely exists. Part of the search work is deciding which requirements are truly non-negotiable and which are preferences, and where the board is willing to trade, for example, taking a strong commercial leader with regulatory literacy and surrounding them with deep regulatory capability. Making these tradeoffs deliberately at the start is far better than discovering the pool’s limits three months in.
Run a Process Strong Candidates Will Stay In
Strong MedTech CEO candidates are usually employed, have options, and are evaluating the board as much as the board is evaluating them. A process that moves slowly, communicates poorly, or subjects candidates to disorganized or repetitive interviews loses exactly the people the board most wants. Boards should agree the timeline, the interview structure, and who is involved before starting, and then hold to it. The board’s conduct during the process is also the candidate’s main evidence about what governance will feel like, which makes it a substantive part of the pitch, not just logistics.
What This Looks Like in Practice
A board preparing a MedTech CEO search aligns explicitly on the mandate and success measures, decides how much direct regulatory and clinical fluency the CEO must have given the company’s stage, distinguishes non-negotiable requirements from preferences before candidates appear, and agrees a timeline and interview structure it will hold to. It treats its own conduct as part of the pitch. It does not begin with an undefined mandate or a profile describing a person who barely exists.
The Mistake Employers Keep Making
The most common mistake is launching the search before the board has genuinely aligned on the mandate, then using candidates as the terrain for an unresolved strategic argument. Directors evaluate the same candidate differently because they are optimizing for different futures, consensus proves elusive, strong candidates sense the disagreement and withdraw, and the search stalls. The board mistakes a definition problem for a candidate supply problem.
Board Decisions to Make Before Starting
| Decision | Why It Matters |
|---|---|
| The mandate and success measures | Different mandates need different leaders |
| Required regulatory fluency | Depends on stage and portfolio |
| Non-negotiables vs preferences | The qualified pool is small |
| Timeline and interview structure | Strong candidates leave slow processes |
| Who is involved and who decides | Prevents late-stage disagreement |
The Bottom Line
Most disappointing MedTech CEO searches are compromised at the definition stage, so before starting, align the board on the mandate, decide explicitly how much regulatory and clinical fluency the CEO needs, separate non-negotiables from preferences given a small pool, and commit to a process strong candidates will stay in. Get this right and the hire becomes a genuine multiplier; get it wrong and no amount of general talent compensates.
Related Reading
For more, see How to Hire a Medical Device CEO Who Understands FDA Pathways, Building a Leadership Team for a Medical Device Company Pre-IPO, Interviewing Medical Device Executives.
Frequently Asked Questions
- Q: What should a board settle before a MedTech CEO search?
- A: The mandate and success measures, the required regulatory and clinical fluency, which requirements are non-negotiable, and the timeline, interview structure, and decision process.
- Q: Why does mandate alignment matter so much?
- A: Because different mandates, commercial scale, regulatory navigation, exit preparation, turnaround, call for different leaders, and unresolved disagreement surfaces as endless debate about candidates.
- Q: How much regulatory fluency does a MedTech CEO need?
- A: It depends on stage and portfolio; a pre-approval company facing a demanding pathway needs far more direct CEO regulatory judgment than a commercial-stage company with a mature portfolio.
- Q: Why calibrate expectations about the pool?
- A: Because candidates combining regulatory judgment, clinical understanding, commercial capability, and CEO-level leadership are scarce, so boards must decide deliberately where they will trade.
- Q: Does the board’s process affect the outcome?
- A: Yes; strong candidates have options and read the board’s conduct as evidence of what governance will feel like, so a slow or disorganized process loses the best people.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
